Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.

Ítems similars

• Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies
  per: Agrawal, Sudhir, et al.
  Publicat: (1997)
• Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration
  per: Wang, Hui, et al.
  Publicat: (1999)
• Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage
  per: Chen, Lihong, et al.
  Publicat: (1998)
• Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A
  per: Tortora, Giampaolo, et al.
  Publicat: (1997)
• Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression.
  per: Chen, L., et al.
  Publicat: (1999)